New Drugs Approved In April


The FDA approved Sevenfact, developed by privately held HEMA Biologics, LLC on April 1, 2020 for the treatment and control of bleeding episodes occurring in adults and adolescents 12 years of age and older with hemophilia A or B with inhibitors.

Sevenfact, an innovative analog of human Factor VIIa, is the first new bypassing agent in over 20 years to be approved to treat Hemophilia A or B Patients with inhibitors.

Bypassing agents are treatments that “bypass” the need for clotting factor treatment.

HEMA Biologics has commercialization and distribution rights for Sevenfact in the U.S. and Canada.

The company is working towards registration of the drug in Europe and other core countries.